As Gilead Sciences gets underway with the key launch of its twice-yearly pre-exposure prophylaxis (PrEP) HIV med, the company ...

Despite the popularity of generic and biosimilar drugs in Europe—the latter of which have struggled to catch on in the ...

Thanks to his trusty Dexcom continuous glucose monitor (CGM), former boy band star Lance Bass is saying “bye bye bye” to ...

A new survey from Takeda due to be presented at the ESMO Gastrointestinal Cancers Congress in Spain this week highlights ...

Despite the slow trickle of updates on President Donald Trump’s proposed pharmaceutical import tariffs, drugmakers have ...

Unicycive Therapeutics has hit a bump on the road in its mission to bring its hyperphosphatemia treatment candidate to ...

The Orphan Cures Act has been added back into the Senate version of President Donald Trump’s “big, beautiful bill” after being ...

Two weeks after Supernus Pharmaceuticals unveiled the proposed acquisition of Sage Therapeutics, all 338 employees from the latter company are being canned, ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

Restricted availability under an FDA-mandated drug safety program has limited the reach of CAR-T cell therapies for certain ...

After blueprinting an injectables facility in North Carolina in 2020, it didn’t take long for Eli Lilly to draw up designs ...

For $45 million upfront, Vor Bio is gaining ex-China rights to RemeGen’s telitacicept, a first-in-class recombinant ...